Pharmaceutical company AstraZeneca PLC is reorganizing its research and development and eliminating about 1,800 R&D jobs as part of a previously announced cost-cutting plan.
The company says that about 550 jobs will be eliminated at its U.S. headquarters in Delaware as it moves primary research and
development elsewhere.
AstraZeneca also says it is closing research sites in the United Kingdom and Sweden as part of a plan announced in January to cut
8,000 more jobs, or 12 percent of its work force, by 2014.
The termination of psychiatric laboratory research in Delaware represents about one-third of the company's R&D work force in the
state, where future R&D efforts will focus on shepherding drugs through clinical trials and regulatory approval.
